News Posts List

ArunA Bio Appoints Al Medwar as Executive Vice President, Corporate and Commercial Development


ATHENS, Ga – March 18, 2019 - ArunA Bio, a leader in the development of exosomes and exosome therapeutics for the treatment of neurodegenerative disorders, today announced the appointment of Al Medwar as Executive Vice President, Corporate and Commercial Development. Mr. Medwar joins the company and its leadership team contributing over 30 years of pharmaceutical industry experience.

Mr. Medwar joins recently appointed Chief Executive Officer, Dr. Mark A. Sirgo, and team as they focus on progressing ArunA’s neural exosome platform toward commercialization, including partnerships with companies in the CNS therapeutic area.

“I am pleased to have Al join the leadership team at ArunA Bio as we move aggressively to utilize our neural exosome platform to develop novel therapeutics to treat serious neurodegenerative disorders through both our internal pipeline and industry collaborations,” said Dr. Sirgo. “Al played a significant role in building BioDelivery Sciences into a fully integrated pharmaceutical company based on a platform technology. I look forward to successfully collaborating with Al again in this new and exciting venture.”

Prior to joining the company, Mr. Medwar was Senior Vice President, Corporate and Business Development for BioDelivery Sciences (Nasdaq: BDSI), where he spent eleven years and played a key role in building the company from a development to a commercial stage enterprise and in securing a number of licensing and partnership deals. In his capacity at BioDelivery Sciences, Mr. Medwar also led investor and public relations working closely with the investor and analyst communities. While at EMD Pharmaceuticals, the U.S. subsidiary of Merck KGaA, Mr. Medwar served as Head of Oncology Marketing, where he was responsible for developing the global market for a pipeline of immuno-oncology products. Earlier in his career, he was also the Marketing Director for Triangle Pharmaceuticals, a start-up company focusing on the development and commercialization of compounds for HIV and hepatitis. Mr. Medwar's pharmaceutical career began in sales at Glaxo Wellcome. He received a BS degree from Cornell University and an MBA from Bentley University.

About ArunA Bio

ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. We are leveraging our proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing our exosomes with small molecules, RNA, oligonucleotides and antibodies. 

For more information, please visit

Lauren Arnold